PL4356969T3 - Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu zakażenia ortomyksowirusami - Google Patents
Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu zakażenia ortomyksowirusamiInfo
- Publication number
- PL4356969T3 PL4356969T3 PL23217305.4T PL23217305T PL4356969T3 PL 4356969 T3 PL4356969 T3 PL 4356969T3 PL 23217305 T PL23217305 T PL 23217305T PL 4356969 T3 PL4356969 T3 PL 4356969T3
- Authority
- PL
- Poland
- Prior art keywords
- orthomyxoviral
- infections
- treatment
- compounds useful
- pyridazinone compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380712P | 2016-08-29 | 2016-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4356969T3 true PL4356969T3 (pl) | 2025-10-20 |
Family
ID=59923494
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL23217305.4T PL4356969T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu zakażenia ortomyksowirusami |
| PL17771587T PL3504214T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
| PL20210329.7T PL3848372T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17771587T PL3504214T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
| PL20210329.7T PL3848372T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11098051B2 (enExample) |
| EP (4) | EP4356969B1 (enExample) |
| JP (3) | JP7221861B2 (enExample) |
| CN (2) | CN109863151B (enExample) |
| AR (1) | AR109438A1 (enExample) |
| CA (1) | CA3035302A1 (enExample) |
| DK (1) | DK4356969T3 (enExample) |
| ES (3) | ES2974494T3 (enExample) |
| FI (1) | FI4356969T3 (enExample) |
| HR (1) | HRP20250885T1 (enExample) |
| HU (1) | HUE072776T2 (enExample) |
| JO (1) | JOP20170169A1 (enExample) |
| LT (1) | LT4356969T (enExample) |
| MX (1) | MX383124B (enExample) |
| PL (3) | PL4356969T3 (enExample) |
| PT (3) | PT3504214T (enExample) |
| SI (3) | SI3504214T1 (enExample) |
| TW (3) | TWI869757B (enExample) |
| UY (2) | UY37378A (enExample) |
| WO (1) | WO2018042303A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105764904B (zh) * | 2013-09-12 | 2020-02-11 | 詹森生物制药有限公司 | 氮杂-吡啶酮化合物及其用途 |
| HK1254961A1 (en) | 2015-12-15 | 2019-08-02 | Shionogi & Co., Ltd. | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| US10759814B2 (en) | 2016-08-10 | 2020-09-01 | Shionogi & Co., Ltd. | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| CN111848615B (zh) | 2018-01-17 | 2022-05-17 | 江西彩石医药科技有限公司 | 吡啶酮衍生物及包含其的抗流感病毒药物组合物 |
| HUE069183T2 (hu) * | 2018-02-28 | 2025-02-28 | Novartis Ag | 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H--pirrolo[1',2':4,5]pirazino[1,2-b]piridazin-3,5-dion származékok és kapcsolódó vegyületek mint orthomyxovírus repikáció gátlók influenza kezelésére |
| CN108440564B (zh) * | 2018-04-11 | 2019-08-06 | 安帝康（无锡）生物科技有限公司 | 被取代的多环氨基甲酰基吡啶酮衍生物及其前药 |
| TW202035424A (zh) * | 2018-10-10 | 2020-10-01 | 美商健生生物製藥公司 | 大環流感內切核酸酶抑制劑 |
| CN111909174B (zh) | 2019-05-08 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物的晶型及制备方法和应用 |
| CN115135646B (zh) * | 2019-12-23 | 2024-05-17 | 石家庄迪斯凯威医药科技有限公司 | 取代的多环化合物及其药物组合物和用途 |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| WO2022105669A1 (zh) * | 2020-11-17 | 2022-05-27 | 南京明德新药研发有限公司 | 含Se大环类化合物 |
| EP4707279A1 (en) * | 2023-05-02 | 2026-03-11 | Albius Sciences Beta Pte. Ltd. | Substituted tricyclic heterocyclic compound as pharmaceutical for treatment or prevention of covid-19 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2225112A (en) | 1938-07-09 | 1940-12-17 | Wright Aeronautical Corp | Air cleaner |
| GB8501542D0 (en) | 1985-01-22 | 1985-02-20 | Erba Farmitalia | 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives |
| AUPM354694A0 (en) | 1994-01-27 | 1994-02-17 | Biota Scientific Management Pty Ltd | Chemical compounds |
| ATE530520T1 (de) | 2001-08-10 | 2011-11-15 | Shionogi & Co | Antivirales mittel |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| AU2005221864A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | HIV integrase inhibitors |
| FR2901795A1 (fr) | 2006-05-30 | 2007-12-07 | Fourtillan Snc | Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique |
| EA019520B1 (ru) | 2008-10-31 | 2014-04-30 | Сионоги Энд Ко., Лтд. | Цефалоспорины, содержащие катехольную группу |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8835461B2 (en) | 2009-03-26 | 2014-09-16 | Shionogi & Co., Ltd. | Substituted 3-hydroxy-4-pyridone derivative |
| JP5737691B2 (ja) * | 2009-06-15 | 2015-06-17 | 塩野義製薬株式会社 | 置換された多環性カルバモイルピリドン誘導体 |
| CN102762568A (zh) | 2009-12-23 | 2012-10-31 | 伊兰药品公司 | 作为polo样激酶的抑制剂的蝶啶酮 |
| TW201201813A (en) | 2010-03-31 | 2012-01-16 | Arqule Inc | Substituted benzo-pyrido-triazolo-diazepine compounds |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| LT2620436T (lt) | 2010-09-24 | 2018-08-10 | Shionogi & Co., Ltd. | Pakeistojo policiklinio karbamoilpiridono darinio provaistas |
| WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| AU2012321762A1 (en) * | 2011-10-12 | 2014-04-17 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase-inhibiting activity |
| US9278996B2 (en) | 2012-09-20 | 2016-03-08 | Celltrion, Inc. | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same |
| EA201591291A1 (ru) | 2013-01-08 | 2015-12-30 | Савира Фармасьютикалз Гмбх | Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания |
| CA2921294C (en) | 2013-08-21 | 2023-05-16 | Alios Biopharma, Inc. | Antiviral compounds |
| CN105530946A (zh) | 2013-09-11 | 2016-04-27 | 南加利福尼亚大学 | 具有高度表达的fas配体的干细胞组合物 |
| CN105764904B (zh) | 2013-09-12 | 2020-02-11 | 詹森生物制药有限公司 | 氮杂-吡啶酮化合物及其用途 |
| AU2014318837B2 (en) | 2013-09-12 | 2019-05-30 | Janssen Biopharma, Inc. | Pyridazinone compounds and uses thereof |
| CA2953862A1 (en) | 2014-07-07 | 2016-01-14 | F. Hoffmann-La Roche Ag | Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases |
| WO2016145103A1 (en) | 2015-03-11 | 2016-09-15 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| WO2017156407A1 (en) | 2016-03-10 | 2017-09-14 | Alios Biopharma, Inc. | Method of preparing aza-pyridone compounds |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| CN109789143A (zh) | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| US10759814B2 (en) | 2016-08-10 | 2020-09-01 | Shionogi & Co., Ltd. | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| JP2019059697A (ja) * | 2017-09-28 | 2019-04-18 | 塩野義製薬株式会社 | 置換された多環性ピリダジン誘導体およびそのプロドラッグ |
| CN110041327B (zh) | 2018-01-17 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |
| CN111848615B (zh) | 2018-01-17 | 2022-05-17 | 江西彩石医药科技有限公司 | 吡啶酮衍生物及包含其的抗流感病毒药物组合物 |
| KR20200126973A (ko) | 2018-02-28 | 2020-11-09 | 니뽄 다바코 산교 가부시키가이샤 | 4-메틸디히드로피리미디논 화합물 및 그의 의약 용도 |
| PE20211456A1 (es) | 2018-02-28 | 2021-08-05 | Hoffmann La Roche | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado |
| CN111741948B (zh) | 2018-02-28 | 2023-11-10 | 日本烟草产业株式会社 | 饱和环稠合的二氢嘧啶酮或二氢三嗪酮化合物及其药物用途 |
| HUE069183T2 (hu) | 2018-02-28 | 2025-02-28 | Novartis Ag | 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H--pirrolo[1',2':4,5]pirazino[1,2-b]piridazin-3,5-dion származékok és kapcsolódó vegyületek mint orthomyxovírus repikáció gátlók influenza kezelésére |
-
2017
- 2017-08-24 JO JOP/2017/0169A patent/JOP20170169A1/ar unknown
- 2017-08-25 CN CN201780065653.XA patent/CN109863151B/zh active Active
- 2017-08-25 CA CA3035302A patent/CA3035302A1/en active Pending
- 2017-08-25 LT LTEP23217305.4T patent/LT4356969T/lt unknown
- 2017-08-25 PT PT177715877T patent/PT3504214T/pt unknown
- 2017-08-25 FI FIEP23217305.4T patent/FI4356969T3/fi active
- 2017-08-25 PL PL23217305.4T patent/PL4356969T3/pl unknown
- 2017-08-25 US US16/328,616 patent/US11098051B2/en active Active
- 2017-08-25 EP EP23217305.4A patent/EP4356969B1/en active Active
- 2017-08-25 HR HRP20250885TT patent/HRP20250885T1/hr unknown
- 2017-08-25 PT PT202103297T patent/PT3848372T/pt unknown
- 2017-08-25 ES ES20210329T patent/ES2974494T3/es active Active
- 2017-08-25 EP EP17771587.7A patent/EP3504214B1/en active Active
- 2017-08-25 EP EP20210329.7A patent/EP3848372B1/en active Active
- 2017-08-25 WO PCT/IB2017/055137 patent/WO2018042303A1/en not_active Ceased
- 2017-08-25 SI SI201730650T patent/SI3504214T1/sl unknown
- 2017-08-25 CN CN202110956692.7A patent/CN113683614B/zh active Active
- 2017-08-25 ES ES17771587T patent/ES2859510T3/es active Active
- 2017-08-25 SI SI201731493T patent/SI3848372T1/sl unknown
- 2017-08-25 HU HUE23217305A patent/HUE072776T2/hu unknown
- 2017-08-25 DK DK23217305.4T patent/DK4356969T3/da active
- 2017-08-25 ES ES23217305T patent/ES3042460T3/es active Active
- 2017-08-25 EP EP25187556.3A patent/EP4640279A3/en active Pending
- 2017-08-25 SI SI201731620T patent/SI4356969T1/sl unknown
- 2017-08-25 US US15/686,652 patent/US10160764B2/en active Active
- 2017-08-25 PL PL17771587T patent/PL3504214T3/pl unknown
- 2017-08-25 MX MX2019002438A patent/MX383124B/es unknown
- 2017-08-25 JP JP2019511749A patent/JP7221861B2/ja active Active
- 2017-08-25 PL PL20210329.7T patent/PL3848372T3/pl unknown
- 2017-08-25 PT PT232173054T patent/PT4356969T/pt unknown
- 2017-08-28 UY UY0001037378A patent/UY37378A/es active IP Right Grant
- 2017-08-28 TW TW112101158A patent/TWI869757B/zh active
- 2017-08-28 TW TW113134345A patent/TW202517646A/zh unknown
- 2017-08-28 TW TW106129086A patent/TWI803467B/zh active
- 2017-08-28 UY UY0001040872A patent/UY40872A/es not_active Application Discontinuation
- 2017-08-29 AR ARP170102385A patent/AR109438A1/es active IP Right Grant
-
2021
- 2021-07-13 US US17/374,237 patent/US11912715B2/en active Active
-
2022
- 2022-11-22 JP JP2022186394A patent/JP2023027102A/ja not_active Withdrawn
-
2024
- 2024-06-13 US US18/743,020 patent/US20250011334A1/en active Pending
-
2025
- 2025-01-23 JP JP2025009843A patent/JP2025081322A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT4356969T (lt) | Kondensuoti tricikliniai piridazinono junginiai, naudotini ortomiksovirusinių infekcijų gydymui | |
| HUS2500039I1 (hu) | Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra | |
| IL269354A (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| IL263972A (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| EP3922634C0 (en) | SUBSTITUTED PYRROLIZINE COMPOUNDS AND THEIR APPLICATIONS | |
| SI3347352T1 (sl) | Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV | |
| MA45192A (fr) | Traitement d'association | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| DK3349758T3 (da) | Fremgangsmåder til behandling af arenaviridae-virusinfektioner | |
| HUE053704T2 (hu) | 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére | |
| DK3490582T3 (da) | Sammensætninger til anvendelse i behandling af myelofibrose | |
| DK3511328T3 (da) | Organiske monobactam-forbindelser til behandling af bakterieinfektioner | |
| HRP20251450T1 (hr) | Beta-d-2'-dezoksi-2'alfa-fluoro-2'-beta-c-supstituirani-2-modificirani-n6-supstituirani purinski nukleotidi za liječenje hcv | |
| IL247111A0 (en) | Preventive or therapeutic agent for kidney disease | |
| EP3661919A4 (en) | SUBSTITUTED FUSION PYRIMIDINE COMPOUNDS AND THEIR USES | |
| EP3548045C0 (en) | COMPOSITIONS FOR USE IN THE TREATMENT OF UROGENITAL INFECTION | |
| IL271863B (en) | Compounds and use thereof for the treatment of microbial infections | |
| DK3436074T3 (da) | Thiazolidforbindelser til behandling af virale infektioner | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| HUE058314T2 (hu) | Pridopidin alkalmazása Rett-szindróma kezelésére | |
| DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
| CY2024037I1 (el) | Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων | |
| EP3523284A4 (en) | NUCLEOBASE DIVALENT COMPOUNDS AND THEIR USES | |
| EP3493823C0 (en) | POSTBIOTIC BASED COMPOUND FOR THE TREATMENT OF OCULAR INFLAMMATION | |
| DK3423060T3 (da) | Imatinib til anvendelse til behandling af slagtilfælde |